Cell therapy weekly: US FDA places clinical hold on SIG-001 hemophilia cell therapy trial

Written by RegMedNet

This week: the US FDA has placed a clinical hold on Sigilon’s Phase I/II study of SIG-001 for hemophilia A, Coya Therapeutics announces that the FDA has granted Orphan Drug Designation to the company’s autologous Treg cell therapy for amyotrophic lateral sclerosis, and researchers have demonstrated how iPSCs and organoids can be used in COVID-19 drug discovery and to investigate differences in SARS-CoV-2 infection. The news highlights: US FDA places clinical hold on SIG-001 hemophilia cell therapy trial Autologous Treg cell therapy given Orphan Drug Designation for amyotrophic lateral sclerosis Researchers model SARS-CoV-2 infection using iPSCs and organoids   US...

To view this content, please register now for access

It's completely free